29 April 2025FeaturesAfricaOlusola Tunmise-Ajani

Commercialising genomic tech in Nigeria

Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO

24 April 2025 Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.

Europe

European court upholds 10x patent after Nanostring appealed injunction

20 March 2025 New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial molecular imaging products.

Europe

‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off

27 February 2025 The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Killing the golden goose of US drug innovation (Part I): Follow the money

Commercialising genomic tech in Nigeria

More on this story

Editor's picks

Editor's picks

More features